De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, et al. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep. 2020;10(1):7073. https://doi.org/10.1038/s41598-020-63759-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(2):115–23. https://doi.org/10.1056/NEJMoa070608.

Article  CAS  PubMed  Google Scholar 

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30(21):2654–63. https://doi.org/10.1200/JCO.2011.39.8545.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134–47. https://doi.org/10.1158/1055-9965.EPI-11-0775.

Article  CAS  PubMed  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33. https://doi.org/10.1056/NEJMoa1706450.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

Article  PubMed  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101.

Article  CAS  PubMed  Google Scholar 

•• Nicolò E, Boscolo Bielo L, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol. 2023;15:17588359231152842. https://doi.org/10.1177/17588359231152842. This landmark trial demonstrated the significant benefit of trastuzumab deruxtecan in a new HER2 classification of HER2-low breast cancer.

Article  PubMed  PubMed Central  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690.

Article  CAS  PubMed  Google Scholar 

•• Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–62. https://doi.org/10.1200/JCO.19.02488. This trial demonstrated the benefit of a targeted therapy agent in the form an oral PARP inhibitor in germline BRCA–mutated metastatic breast cancer. It is a landmark study demonstrating the promise of targeted therapy.

Article  CAS  PubMed  Google Scholar 

Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–66. https://doi.org/10.1093/annonc/mdz012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, et al. A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status. Oncol Ther. 2021;9(2):575–89. https://doi.org/10.1007/s40487-021-00162-4.

Article  PubMed  PubMed Central  Google Scholar 

• Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med. 2022;11(6):1474–83. https://doi.org/10.1002/cam4.4566. This study has the most well-characterized and complete data published on a germline BRCA and HER2-positive breast cancer cohort. The data on epidemiology and prognosis of this cohort has contributed significantly to the understanding of this small but significant population.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, et al. Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. Breast. 2022;65:145–50. https://doi.org/10.1016/j.breast.2022.07.012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025–31. https://doi.org/10.1245/s10434-019-07549-8.

Article  PubMed  PubMed Central  Google Scholar 

Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, Version 3.2023. J Natl Compr Canc Netw. 2023;18(4):380–91. https://doi.org/10.6004/jnccn.2020.0017.

Article  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364–82. https://doi.org/10.5858/arpa.2018-0902-SA.

Article  PubMed  Google Scholar 

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. https://doi.org/10.1200/JCO.2013.50.9984.

Article  PubMed  Google Scholar 

Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286. https://doi.org/10.1016/j.ctrv.2021.102286.

Article  CAS  PubMed  Google Scholar 

Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022;163:35–43. https://doi.org/10.1016/j.ejca.2021.12.022.

Article  CAS  PubMed  Google Scholar 

Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer. 2022;29(2):234–41. https://doi.org/10.1007/s12282-021-01303-3.

Article  PubMed  Google Scholar 

Wang C, Mu Z, Ye Z, Zhang Z, Abu-Khalaf MM, Silver DP, et al. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020;181(3):679–89. https://doi.org/10.1007/s10549-020-05662-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, et al. mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Cancers. 2020;12(7). https://doi.org/10.3390/cancers12071902.

Evans DG, Lalloo F, Howell S, Verhoef S, Woodward ER, Howell A. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Res Treat. 2016;155(3):597–601. https://doi.org/10.1007/s10549-016-3697-z.

Article  CAS  PubMed  Google Scholar 

Whitaker K, Obeid E, Goldstein L, Daly M. Abstract P6-08-21: Prevalence of HER2 positivity in germline BRCA 1/2-associated breast cancers (g BRCA1/2-BC). Cancer Res. 2020;80(4_Supplement):P6-08-21.

Article  Google Scholar 

•• Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014;16(6):3416. https://doi.org/10.1186/s13058-014-0492-9. This trial demonstrated the benefit of a targeted therapy agent in the form an oral PARP inhibitor in germline BRCA–mutated HER2-negative breast cancer in the adjuvant setting. It is a landmark study demonstrating the promise of targeted therapy.

Article  PubMed  PubMed Central  Google Scholar 

Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–80. https://doi.org/10.1016/S1470-2045(17)30891-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonderstrup IMH, Jensen MR, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, et al. Subtypes in BRCA-mutated breast cancer. Hum Pathol. 2019;84:192–201. https://doi.org/10.1016/j.humpath.2018.10.005.

Article  CAS  PubMed  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with. N Engl J Med. 2021;384(25):2394–405. https://doi.org/10.1056/NEJMoa2105215.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628–37. https://doi.org/10.1038/s41591-018-0009-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, et al. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. Cancer Biol Ther. 2018;19(6):525–33. https://doi.org/10.1080/15384047.2018.1436024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litton JK,